1. Home
  2. VTSI vs KLRS Comparison

VTSI vs KLRS Comparison

Compare VTSI & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VirTra Inc.

VTSI

VirTra Inc.

N/A

Current Price

$2.62

Market Cap

51.0M

ML Signal

N/A

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

N/A

Current Price

$2.02

Market Cap

44.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VTSI
KLRS
Founded
1993
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.0M
44.5M
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
VTSI
KLRS
Price
$2.62
$2.02
Analyst Decision
Strong Buy
Buy
Analyst Count
2
8
Target Price
$6.25
★ $17.67
AVG Volume (30 Days)
26.9K
★ 70.5K
Earning Date
11-12-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 75.70
EPS
★ N/A
N/A
Revenue
★ $185,971.00
$165,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$27.40
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.54
$1.78
52 Week High
$6.08
$11.88

Technical Indicators

Market Signals
Indicator
VTSI
KLRS
Relative Strength Index (RSI) 42.00 36.04
Support Level $2.54 N/A
Resistance Level $2.82 $4.37
Average True Range (ATR) 0.12 0.15
MACD 0.01 0.04
Stochastic Oscillator 32.14 43.69

Price Performance

Historical Comparison
VTSI
KLRS

About VTSI VirTra Inc.

VirTra Inc is a U.S.-based company that is engaged in the sale and development of judgmental use-of-force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company operates in six segments, which include Simulators and Accessories, Extended Service, Customized software and Custom content, Installation and Training, Design and Prototyping, and Subscription Training Equipment Partnership. The majority of its revenue is generated from the Simulators and Accessories segment.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: